Catalyst Pharmaceuticals (CPRX) Projected to Post Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.32 per share and revenue of $134.20 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX opened at $22.94 on Wednesday. The company has a market cap of $2.74 billion, a P/E ratio of 19.44, a PEG ratio of 3.46 and a beta of 0.80. Catalyst Pharmaceuticals has a one year low of $13.49 and a one year high of $24.64. The business’s 50-day simple moving average is $22.21 and its 200 day simple moving average is $21.19.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Bank of America restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They set an “outperform” rating and a $28.00 price objective on the stock. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Finally, Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.25.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.